Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • ado-trastuzumab emtansine

    - PMLiVE

    Lilly announces new study data on Inluriyo in metastatic breast cancer

    The five-year survival rate for metastatic breast cancer is 30%

    - PMLiVE

    AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer

    Around one in five breast cancer cases are HER2-positive

    - PMLiVE

    Medicus Pharma completes patient enrolment for basal cell carcinoma trial

    Interim results have shown over 60% clinical clearance in patients treated with SkinJect

    - PMLiVE

    FDA approves first gene therapy for Wiskott-Aldrich syndrome

    Symptoms of the rare disease include bleeding, eczema and frequent infections

    - PMLiVE

    Researchers at University of Geneva develop test platform for cancer treatments

    The new platform could speed up testing while reducing the need for animal models

    - PMLiVE

    FDA launches TEMPO digital health pilot

    Digital technologies can improve remote patient care for those with chronic diseases

    - PMLiVE

    Roche’s Columvi improves survival in large B-cell lymphoma

    Approximately 160,000 people are diagnosed with this aggressive form of cancer each year

    - PMLiVE

    Roche receives FDA clearance for whooping cough test

    There are around 24.1 million cases of whooping cough annually, with around 170,000 deaths

    - PMLiVE

    Richard Pazdur, FDA’s drug evaluation chief, to leave FDA just weeks into new role

    Pazdur was previously head of the FDA’s Oncology Center of Excellence

    - PMLiVE

    Merck KGaA given FDA Fast Track designation for generalised myasthenia gravis drug

    Cladribine capsules could become the first ever oral treatment for gMG

    - PMLiVE

    Gilead reports Trodelvy breast cancer trial missed primary survival endpoint

    The drug treatment is being evaluated in several ongoing phase 3 trials

    - PMLiVE

    Johnson & Jonson secures FDA approval for multiple myeloma treatment

    Support for first and only high-risk smouldering multiple myeloma treatment came from positive phase 3 trial results

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links